These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 23266403)

  • 1. Strategies for anti-fibrotic therapies.
    Rosenbloom J; Mendoza FA; Jimenez SA
    Biochim Biophys Acta; 2013 Jul; 1832(7):1088-103. PubMed ID: 23266403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human Fibrotic Diseases: Current Challenges in Fibrosis Research.
    Rosenbloom J; Macarak E; Piera-Velazquez S; Jimenez SA
    Methods Mol Biol; 2017; 1627():1-23. PubMed ID: 28836191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endothelial to Mesenchymal Transition (EndoMT) in the Pathogenesis of Human Fibrotic Diseases.
    Piera-Velazquez S; Mendoza FA; Jimenez SA
    J Clin Med; 2016 Apr; 5(4):. PubMed ID: 27077889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Narrative review: fibrotic diseases: cellular and molecular mechanisms and novel therapies.
    Rosenbloom J; Castro SV; Jimenez SA
    Ann Intern Med; 2010 Feb; 152(3):159-66. PubMed ID: 20124232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diverse origins of the myofibroblast—implications for kidney fibrosis.
    Falke LL; Gholizadeh S; Goldschmeding R; Kok RJ; Nguyen TQ
    Nat Rev Nephrol; 2015 Apr; 11(4):233-44. PubMed ID: 25584804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Into the matrix: targeting fibroblasts in pulmonary fibrosis.
    Sivakumar P; Ntolios P; Jenkins G; Laurent G
    Curr Opin Pulm Med; 2012 Sep; 18(5):462-9. PubMed ID: 22847104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cytokines of pulmonary fibrosis: Much learned, much more to learn.
    Luzina IG; Todd NW; Sundararajan S; Atamas SP
    Cytokine; 2015 Jul; 74(1):88-100. PubMed ID: 25543535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The origin of renal fibroblasts/myofibroblasts and the signals that trigger fibrosis.
    Sun YB; Qu X; Caruana G; Li J
    Differentiation; 2016 Sep; 92(3):102-107. PubMed ID: 27262400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyrosine kinase signaling in fibrotic disorders: Translation of basic research to human disease.
    Beyer C; Distler JH
    Biochim Biophys Acta; 2013 Jul; 1832(7):897-904. PubMed ID: 22728287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TGF-β-Induced Endothelial-Mesenchymal Transition in Fibrotic Diseases.
    Pardali E; Sanchez-Duffhues G; Gomez-Puerto MC; Ten Dijke P
    Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29039786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endothelial to mesenchymal transition (EndoMT) in the pathogenesis of Systemic Sclerosis-associated pulmonary fibrosis and pulmonary arterial hypertension. Myth or reality?
    Jimenez SA; Piera-Velazquez S
    Matrix Biol; 2016 Apr; 51():26-36. PubMed ID: 26807760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug targeting to myofibroblasts: Implications for fibrosis and cancer.
    Yazdani S; Bansal R; Prakash J
    Adv Drug Deliv Rev; 2017 Nov; 121():101-116. PubMed ID: 28720422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding the origin, activation and regulation of matrix-producing myofibroblasts for treatment of fibrotic disease.
    Kramann R; DiRocco DP; Humphreys BD
    J Pathol; 2013 Nov; 231(3):273-89. PubMed ID: 24006178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Potential of sGC Modulators for the Treatment of Age-Related Fibrosis: A Mini-Review.
    Sandner P; Berger P; Zenzmaier C
    Gerontology; 2017; 63(3):216-227. PubMed ID: 27784018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sphingosine-1-phosphate as a mediator involved in development of fibrotic diseases.
    Takuwa Y; Ikeda H; Okamoto Y; Takuwa N; Yoshioka K
    Biochim Biophys Acta; 2013 Jan; 1831(1):185-92. PubMed ID: 22735357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic activity of the histone deacetylase inhibitor SB939 on renal fibrosis.
    Kang SW; Lee SM; Kim JY; Kim SY; Kim YH; Kim TH; Kang MS; Jang WH; Seo SK
    Int Immunopharmacol; 2017 Jan; 42():25-31. PubMed ID: 27855304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stem cell-based therapy for fibrotic diseases: mechanisms and pathways.
    Taherian M; Bayati P; Mojtabavi N
    Stem Cell Res Ther; 2024 Jun; 15(1):170. PubMed ID: 38886859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-fibrotic actions of relaxin.
    Samuel CS; Royce SG; Hewitson TD; Denton KM; Cooney TE; Bennett RG
    Br J Pharmacol; 2017 May; 174(10):962-976. PubMed ID: 27250825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibroblast biology in pterygia.
    Kim KW; Park SH; Kim JC
    Exp Eye Res; 2016 Jan; 142():32-9. PubMed ID: 26675401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human xylosyltransferase-I - a new marker for myofibroblast differentiation in skin fibrosis.
    Faust I; Roch C; Kuhn J; Prante C; Knabbe C; Hendig D
    Biochem Biophys Res Commun; 2013 Jul; 436(3):449-54. PubMed ID: 23747722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.